In contrast, treatment of cells with the NF-κB inhibitor BAY 11–7082 strongly reduced the ability of CD95 to activate STAT1 in CD95 stimulated MCF-7 cells (Fig. 3B), and two other breast cancer cell lines we recently showed activate STAT1 in response to CD95 stimulation (Fig. 3C)29. Here, STAT1 is linked to breast carcinoma.